MedTrace Logo

To Demonstrate the Relative Bioavailability of Fluoxetine Hydrochloride Capsules, 40 mg

NCT00947076 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-03-28

No results posted yet for this study

Summary

To demonstrate the relative bioavailability of fluoxetine hydrochloride capsules, 40 mg.

Conditions

Interventions

DRUG

Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)

DRUG

Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)

Sponsors & Collaborators

Principal Investigators

  • Ronald Goldwater, M.D. · PharmaKinetics Laboratories Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-02-28
Primary Completion
2001-04-30
Completion
2001-04-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00947076 on ClinicalTrials.gov